Amplatzer Cardiac Plug (ACP)
Prospective, randomized controlled trial to evaluate the safety and effectiveness of a device in preventing thrombus from migrating from the left atrial appendage (LAA) in subjects who have nonvalvular atrial fibrillation and is an alternative to long-term anticoagulation therapy.
Principal investigators: Ethan Korngold, M.D., and Randolph Jones, M.D.
Sponsor: St. Jude
Contacts: Carmen Dahlberg, CRC, clinical research coordinator 503-216-7370, or Ellen Muir, CCRC, clinical research coordinator, 503-216-2110
EVOLVE II
Prospective, randomized trial to compare the safety and effectiveness of two drug-eluting stents in the treatment of subjects with atherosclerotic lesion(s) in native coronary arteries: the SYNERGY Everolimus-Eluting Stent and the PROMUS Element Plus Everolimus-Eluting Stent.
Principal investigator: Robert Hodson, M.D.
Sponsor: Boston Scientific Corp.
Contact: Michelle Dixon, CCRC, clinical research coordinator, 503-215-6746
The PARTNER II Trial
Placement of AoRTic TraNscathetER Valves Trial. The safety and effectiveness of the SAPIEN Transcatheter Heart Valve with NovaFlex and Ascendra 2 delivery systems (transfemoral and transapical) in intermediate risk for aortic valve surgery and patients who cannot undergo surgery.
Principal investigators: Robert Hodson, M.D., and Jeffrey Swanson, M.D.
Co-investigators: Ethan Korngold, M.D., and Eric Kirker, M.D.
Sponsor: Edwards Lifesciences, LLC
Contacts: Angela Redd, CCRC, clinical research coordinator, 503-216-2170, or Heather Aiona, CCRC, clinical research coordinator, 503-216-2099
ABSORB randomized controlled trial
A clinical evaluation of ABSORB™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of subjects with de novo native coronary artery lesions
Principal investigator: Ethan Korngold, M.D.
Sponsor: Abbott Vascular
Contact: Heather Aiona, CCRC, clinical research coordinator, 503-216-2099
RESPECT
Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment
Enrollment criteria: Subjects with PFO who have had a "cryptogenic stroke" within the last 270 days. Call for more specific inclusion/exclusion criteria.
Principal investigator: Ted Lowenkopf, M.D.
Sponsor: AGA Medical Corp.
Contact: Angela Redd, CCRC, clinical research coordinator, 503-216-2170
The DAPT Study
A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions
Enrollment criteria
Patients undergoing PCI with either DES or BMS without known contraindication to dual antiplatelet therapy for at least 30 months after enrollment and stent implantation
Principal investigator:
Todd Caulfield, M.D.
Sponsor: Harvard Clinical Research Institute (HCRI)
Contact:
Heather Aiona, CCRC, clinical research coordinator, 503-216-2099
SPIRIT PRIME (in follow-up)
A Clinical Evaluation of the XIENCE PRIME™ and XIENCE PRIME™ LL Everolimus Eluting Coronary Stent System
Inclusion criteria
- Patients with one or two de novo lesions each in a different epicardial vessel
- Must have TIMI flow of 1 and diameter stenosis =50% and <100%
- Exclusion criteria
- MI with enzymes still elevated
- LVEF <30%
- TIA/CVA in past 6 months
- On chronic anticoagulation therapy (Coumadin or heparin)
Principal investigator: Richard Sohn, M.D., FACC
Sponsor: Abbott Vascular
Contact: Ellen Muir, CCRC, clinical research coordinator, 503-216-2110
TAXUS PERSEUS (in follow-up)
A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
Principal investigator: Richard Sohn, M.D., FACC
Sponsor: Boston Scientific Corp.
PLATINUM (in follow-up)
A Prospective, Randomized, Multi-Center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of Up to Two de novo Coronary Artery Lesions
Principal investigator: Richard Sohn, M.D., FACC
Sponsor: Boston Scientific Corp.